Polaris Sales Agreement

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Retrieved on: 
Monday, September 18, 2023

ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”).

Key Points: 
  • ATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”).
  • The Company has initiated the 10-day termination process under the Sales Agreement, with the official termination taking effect on September 28, 2023.
  • The Company will make no sales under the Sales Agreement during this period.
  • Prosecuting a patent application covering the treatment of Long-COVID and Alzheimer’s disease with combination antiviral formulations.

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 10, 2023

ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.

Key Points: 
  • ET -
    ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
  • Research and development expenses for the second quarter of 2023 were $0.6 million, compared to $2.4 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $0.9 million, compared to $1.3 million for the second quarter of 2022.
  • Virios Therapeutics management will host a webcast and conference call on August 10, 2023, at 8:30 a.m.

Endeavour Silver Announces At-the-Market Offering of up to US$60 Million

Retrieved on: 
Tuesday, June 27, 2023

The Common Shares will be distributed at the market prices prevailing at the time of each sale and, as a result, prices may vary as between purchasers and during the period of distribution.

Key Points: 
  • The Common Shares will be distributed at the market prices prevailing at the time of each sale and, as a result, prices may vary as between purchasers and during the period of distribution.
  • No offers or sales of Common Shares will be made in Canada on the Toronto Stock Exchange (the “TSX”) or other trading markets in Canada.
  • The Company will pay the Agents compensation, or allow a discount, of 2.00% of the gross sales price per Common Share sold under the Sales Agreement.
  • Sales under the Sales Agreement remain subject to necessary regulatory approvals, including the approval of the TSX and the NYSE.

enCore Energy Announces Agreement for At-The-Market Offering

Retrieved on: 
Tuesday, June 27, 2023

The ATM Facility can be in effect until the aggregate gross sales proceeds of common shares sold pursuant to the Sales Agreement equals US$70,000,000, unless terminated prior to such date by enCore or otherwise in accordance with the Sales Agreement.

Key Points: 
  • The ATM Facility can be in effect until the aggregate gross sales proceeds of common shares sold pursuant to the Sales Agreement equals US$70,000,000, unless terminated prior to such date by enCore or otherwise in accordance with the Sales Agreement.
  • William M. Sheriff, enCore's Executive Chairman stated: "The At-The-Market (ATM) Offering provides enCore access to funds with greater flexibility and lower costs than more traditional financings.
  • 333-272609), dated June 12, 2023 and June 20, 2023, respectively (collectively, the "Offering Documents").
  • Before you invest, you should read the Offering Documents and the documents incorporated therein for more complete information about the Company and the Offering.

Sprott Physical Silver Trust Updates Its “At-the-Market” Equity Program

Retrieved on: 
Thursday, April 6, 2023

TORONTO, April 06, 2023 (GLOBE NEWSWIRE) -- Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Silver Trust (NYSE: PSLV) (TSX: PSLV / PSLV.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical silver bullion, today announced that it has updated its at-the-market equity program to issue up to US$1 billion of units of the Trust (“Units”) in the United States and Canada.

Key Points: 
  • TORONTO, April 06, 2023 (GLOBE NEWSWIRE) -- Sprott Asset Management LP (“Sprott Asset Management”), a subsidiary of Sprott Inc., on behalf of the Sprott Physical Silver Trust (NYSE: PSLV) (TSX: PSLV / PSLV.U) (the “Trust”), a closed-ended mutual fund trust created to invest and hold substantially all of its assets in physical silver bullion, today announced that it has updated its at-the-market equity program to issue up to US$1 billion of units of the Trust (“Units”) in the United States and Canada.
  • The Trust intends to use the proceeds from the ATM Program, if any, to acquire physical silver bullion in accordance with the Trust's objective and subject to the Trust's investment and operating restrictions.
  • The offering under the ATM Program is being made pursuant to a prospectus supplement dated April 6, 2023 (the “U.S.
  • Before you invest, you should read the Offering Documents and other documents that the Trust has filed for more complete information about the Trust, the Sales Agreement and the ATM Program.

GreenPower Reports Record Deliveries of More Than 120 All-Electric Vehicles in Q4

Retrieved on: 
Monday, April 10, 2023

"GreenPower demonstrates strong growth with our third consecutive quarter of record deliveries with more than 120 vehicles delivered to customers across the country.

Key Points: 
  • "GreenPower demonstrates strong growth with our third consecutive quarter of record deliveries with more than 120 vehicles delivered to customers across the country.
  • This increase represents a six-fold increase from a year ago," said GreenPower CEO Fraser Atkinson.
  • "As we increasingly book new orders and consistently deliver these all-electric vehicles at accelerated rates, GreenPower separates itself from the field as a market leader."
  • Pursuant to the Sales Agreement, a cash commission of $104,381 was paid to the Agent resulting in net proceeds of $3,691,300.

Medicenna Establishes At-the-Market Sales Facility

Retrieved on: 
Friday, February 17, 2023

Medicenna will determine, at its sole discretion, the time, minimum price and maximum number of common shares to be sold under the ATM Offering.

Key Points: 
  • Medicenna will determine, at its sole discretion, the time, minimum price and maximum number of common shares to be sold under the ATM Offering.
  • No offers or sales of common shares will be made in Canada or through the facilities of the Toronto Stock Exchange (the “TSX”).
  • The ATM Offering will terminate upon the earlier of the sale of US$10 million of common shares subject to the Sales Agreement or the termination of the Sales Agreement, as permitted therein.
  • The preliminary ATM Prospectus Supplement (together with the related base shelf prospectus) is also available on the SEC's website (www.sec.gov).

GreenPower Delivers a Record 101 All-Electric Vehicles in its Third Quarter

Retrieved on: 
Tuesday, January 10, 2023

LOS ANGELES, Jan. 10, 2023 /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ: GP) (TSXV: GPV) ("GreenPower"), a leading manufacturer and distributor of zero-emission, electric-powered, medium and heavy-duty vehicles, today announced delivery of 101 vehicles for its third quarter ended December 31, 2022, a substantial increase over prior quarters.

Key Points: 
  • LOS ANGELES, Jan. 10, 2023 /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ: GP) (TSXV: GPV) ("GreenPower"), a leading manufacturer and distributor of zero-emission, electric-powered, medium and heavy-duty vehicles, today announced delivery of 101 vehicles for its third quarter ended December 31, 2022, a substantial increase over prior quarters.
  • "GreenPower made significant progress in the third quarter and we already have deliveries scheduled for more than 100 vehicles in the current quarter," said GreenPower CEO Fraser Atkinson.
  • During the third quarter GreenPower concluded Round 2 of the West Virginia School Bus Pilot Project.
  • GreenPower also continued to increase its dealer network across the country during the quarter.

Quantum Computing Inc. Files $25M At-The-Market Issuance Sales Agreement

Retrieved on: 
Tuesday, December 6, 2022

“At-the-Market offerings are attractive because sales, if any, are made at prevailing market prices, without discounts, warrants, or other consideration.

Key Points: 
  • “At-the-Market offerings are attractive because sales, if any, are made at prevailing market prices, without discounts, warrants, or other consideration.
  • Quantum Computing Inc. (QCI) (NASDAQ: QUBT) is a full-stack quantum software and hardware company on a mission to accelerate the value of quantum computing for real-world industry applications, delivering the future of quantum computing, today.
  • The combination of QCI’s flagship ready-to-run software product, Qatalyst with its industry-leading Entropy Quantum Computing (EQC) system, Dirac 1 , provides a broadly accessible and affordable enterprise quantum solution capable of solving real business problems now.
  • Qatalyst™ is the trademark of Quantum Computing Inc. All other trademarks are the property of their respective owners.

RM plc: Proposed sale of the RM Integris and RM Finance Business

Retrieved on: 
Monday, November 28, 2022

RM plc, a leading supplier of technology and resources to the education sector (LSE: RM) ("RM", the "Company" or, together with its subsidiary undertakings, the "Group"), today announces that it has conditionally agreed to sell the RM Integris and RM Finance Business and related assets of its principal trading subsidiary, RM Education Limited ("RMEL"), (the "RM Integris and RM Finance Business") to The Key Support Services Limited ("The Key").

Key Points: 
  • RM plc, a leading supplier of technology and resources to the education sector (LSE: RM) ("RM", the "Company" or, together with its subsidiary undertakings, the "Group"), today announces that it has conditionally agreed to sell the RM Integris and RM Finance Business and related assets of its principal trading subsidiary, RM Education Limited ("RMEL"), (the "RM Integris and RM Finance Business") to The Key Support Services Limited ("The Key").
  • Sale of the RM Integris and RM Finance Business to The Key for a consideration of up to 16.0 million in cash.
  • We thank all our employees for their excellent work, especially those in the RM Integris and RM Finance Business."
  • The Sale of the RM Integris and RM Finance Business is part of a wider restructure of RM's Technology business under the Group's transformation strategy which was announced in February 2022.